Journal of Antimicrobial Chemotherapy (2003) 51, 13-20
© 2003 The British Society for Antimicrobial Chemotherapy
Supplement |
The quinolones: decades of development and use
1 Division of Microbiology and Infectious Diseases, University Hospital, Queens Medical Centre, Nottingham NG7 2UH; 2 Department of Health Sciences, University of York, Heslington, York YO10 5DD, UK
Abstract
The discovery of nalidixic acid in 1962, and its introduction for clinical use in 1967, marks the beginning of five decades of quinolone development and use. It was not until the discovery and licensing of the fluoroquinolones in the 1970s and 1980s that these drugs began to establish their place in the armamentarium of clinically useful antimicrobials. At the beginning of the 21st century, in their fifth decade of discovery and use, our understanding of structure–function relationships has improved, and better compounds, in terms of both spectrum of antimicrobial cover and pharmacokinetics, have been developed. The clinical utility of this expanding class of antimicrobial agents, and the lower propensity for the development of resistance with the ‘newer’ fluoroquinolones will need to be continually monitored in the changing therapeutic environment. Antibiotic drug choice will remain difficult in the presence of increasing resistance, but the introduction of the new fluoroquinolones has created a new and exciting era in antimicrobial treatment. The role of these agents has already been acknowledged in a number of clinical guidelines, and appropriate use of these agents may help to preserve their clinical utility, enabling them to realize their full therapeutic potential.
Footnotes
* Correspondence address: 11 Southwood Mansions, Southwood Lane, Highgate, London N6 5SZ, UK. Tel: +44-208-341-7443; Fax: +44-208-374-6113
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Kawai, S. Yamada, A. Ishidoshiro, Y. Oyamada, H. Ito, and J.-i. Yamagishi Cell-wall thickness: possible mechanism of acriflavine resistance in meticillin-resistant Staphylococcus aureus J. Med. Microbiol., March 1, 2009; 58(3): 331 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-y. Ohta, Y. Imamura, N. Okudaira, R. Atsumi, K. Inoue, and H. Yuasa Functional Characterization of Multidrug and Toxin Extrusion Protein 1 as a Facilitative Transporter for Fluoroquinolones J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 628 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Davidson, E. Dassa, C. Orelle, and J. Chen Structure, Function, and Evolution of Bacterial ATP-Binding Cassette Systems Microbiol. Mol. Biol. Rev., June 1, 2008; 72(2): 317 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Vidaillac, J. Guillon, C. Arpin, I. Forfar-Bares, B. B. Ba, J. Grellet, S. Moreau, D.-H. Caignard, C. Jarry, and C. Quentin Synthesis of Omeprazole Analogues and Evaluation of These as Potential Inhibitors of the Multidrug Efflux Pump NorA of Staphylococcus aureus Antimicrob. Agents Chemother., March 1, 2007; 51(3): 831 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-S. Park, H.-J. Kim, M.-J. Seol, D.-R. Choi, E.-C. Choi, and J.-H. Kwak In Vitro and In Vivo Antibacterial Activities of DW-224a, a New Fluoronaphthyridone. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2261 - 2264. [Abstract] [Full Text] [PDF]
|
|